Adial Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on addiction therapeutics, has recently announced the receipt of the final development cost reimbursement payment of $350,000 from Adovate, LLC. This payment marks a significant milestone in their business agreement and sets the stage for potential groundbreaking discoveries in addiction and related disorders. In addition to this immediate injection of funds, Adial Pharmaceuticals stands to gain up to $83 million in total consideration, including milestone payments and equity stakes in Adovate.
The Asset Purchase Agreement
The payment received by Adial Pharmaceuticals is part of the asset purchase agreement executed with Adovate for the acquisition of the assets and business of Purnovate, Inc. a wholly-owned subsidiary of Adial. Per the terms of the agreement, Adial Pharmaceuticals is also en
Comments